MINDCURE announces its addition to the OTCQX Best Markets tier.
Exploring the companies and themes that make up this emerging and exciting new sector
California Could Decriminalize Drug “Magic Mushrooms” as Early as Next Year
The seeds have been planted for another California law that could loosen restrictions on the use of recreational drugs in the United States.
Novamind Opens 6th Integrative Psychiatry Clinic, Adds 3rd Clinical Research Site
Novamind opens the 6th mental health clinic in its Cedar Psychiatry network, located in Murray, Utah. Novamind is now projecting a total of 65,000 clinic visits this year.
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
Private company Delix Therapeutics raises $70 million, focusing on non-hallucinatory candidates to treat brain disorders.
MINDCURE Launches "Desire Project" To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy
MINDCURE launches "Desire Project", taking a psychotherapy approach to female hypocactive sexual disorder.
MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
MindMed provides updates on two of its research initiatives, in partnership with the Liechti Lab (Switzerland).
Levitee Labs Announces DTC Eligibility Approval
Levitee Labs announces that its shares are now eligible for clearing through the DTC.
Novamind Announces DTC Eligibility for its Common Shares
Novamind announces that its shares are now eligible for electronic clearing through the DTC.
Are Psychedelic Stocks About To Heat Up (Again)?
Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.
Feds Fund Study Into Whether Psilocybin Can Help People Quit Smoking Cigarettes
A top federal drug agency is funding a study into how psilocybin could help people quit smoking cigarettes—one of the latest examples of the government’s growing interest in psychedelic therapy.
Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
For most of his adult life, Aaron Presley, age 34, felt like a husk of a person, a piece of "garbage."
Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data
Mydecine announces filing of patent application for psilocybin-based MYCO-003. Pre-clinical data is showing MYCO-003 to work better than pure psilocybin.